Arizona State University, in partnership with University of Texas Health San Antonio Cancer Center, and the Mayo Clinic, began recruitment for an 8-week study that aims to explore the practicality and impact of different non-pharmacologic strategies (i.e., mobile app, education) to reduce fatigue in MPN patients. We have had an incredible response thus far, with… Read More »A NEW STUDY TO EXPLORE THE EFFECTS OF NON-PHARMACOLOGIC STRATEGIES FOR MPN PATIENT SYMPTOM BURDEN.
Hoffman-La Roche has a new trial they have initiated for Polycythemia Vera, for those who are either resistant to or intolerant of Hydroxyurea. The drug – NP39761 or Idasanutlin – is being tested in a Phase 1, single arm trial. The drug is taken orally by patients, and disrupts certain cancer causing pathways relevant to… Read More »NEW DRUG TRIAL FOR POLYCYTHEMIA VERA INITIATED
September 18, 2017 The FDA is working hard to incorporate the patient voice in their mission of approving safe and effective new drugs. The FDA has newly formed the Oncology Center of Excellence that has, as one of its departments, the Office of Patient Outcomes. This office reached out through the FDA’s Patient Liaison Program… Read More »MPN RESEARCH FOUNDATION VISITS THE FDA
December 12, 2016 At this year’s ASH Annual Meeting there were a number of updates about drugs in clinical trials. Some abstract highlights are below. To receive the ASH report from our Scientific Advisory John Crispino, PhD, make sure you sign up for our mailing list. We were happy to have one of our CRISPR… Read More »MPN NEWS FROM ASH 2016
November 15, 2016 Katya Ravid of Boston University School of Medicine has just published an exciting discovery, proving that it is possible to detect bone marrow fibrosis IN A MOUSE MODEL OF MYELOFIBROSIS using IN VIVO MRI. “While we are encouraged by these findings in mice, there is still much to be done in… Read More »KATYA RAVID MAKES DISCOVERY ON USING MRI TO DETECT MYELOFIBROSIS
MPN Research Foundation congratulates our MPN Challenge™ grantees Zhijian Qian, a PhD from the University of Illinois at Chicago and Ann Mullally a MD at The Brigham and Women’s Hospital for receiving the 2016 ASH Bridge Grant. They are 2 of 9 investigators who have received the latest round of ASH Bridge grants to sustain their promising research programs that… Read More »2016 ASH BRIDGE GRANT PROGRAM
July 5, 2016 Researchers at Stanford have partnered with the genetic sequencing company 23andMe to study of 726 people with PV, ET and MF, compared to a control population from the 23andMe dataset. Dr. Jason Gotlib reports in Blood that individuals found in the control without an MPN, but with the JAK2 mutation have a predisposition… Read More »23ANDME PARTNERS WITH STANFORD RESEARCHER ON MPN
July 4, 2016 Promedior is currently recruiting patients for the PROMOTE study, a phase 2 trial of PRM-151 in subjects with primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF. PRM-151 is a recombinant form of pentraxin-2 (PTX-2), a protein that circulates in the blood stream that helps to regulate tissue repair. PTX-2 levels have… Read More »ANTI-FIBROTIC DRUG RECRUITING PATIENTS ACROSS THE COUNTRY FOR PHASE 2 CLINICAL TRIAL
